Following the FDA’s September announcement of a crackdown on direct-to-consumer drug marketing practices and the subsequent flurry of untitled and warning letters criticizing dozens of Big Pharma ads, ...
The FDA’s Office of Prescription Drug Promotion issued an Untitled Letter, backdated to September 23, to Tracey M. Henderson, MS, MBA – AstraZeneca’s promotional regulatory affairs review director, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback